Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$2.44 USD

2.44
1,622,130

-0.07 (-2.79%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $2.44 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Options Traders Expect Huge Moves in Editas Medicine (EDIT) Stock

by Zacks Equity Research

Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.

    Zacks Equity Research

    Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 18.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Zacks Equity Research

      Is a Beat in Store for Ionis (IONS) This Earnings Season?

      by Zacks Equity Research

      On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.

        Zacks Equity Research

        Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings?

        by Zacks Equity Research

        On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.

          Zacks Equity Research

          Editas Medicine (EDIT) Enters Oversold Territory

          by Zacks Equity Research

          Editas Medicine, Inc. (EDIT) has been on a bit of a cold streak lately

            Zacks Equity Research

            Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

            by Zacks Equity Research

            Is (EDIT) Outperforming Other Medical Stocks This Year?

              Zacks Equity Research

              Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

              by Zacks Equity Research

              Sector ETF report for ARKG

                Zacks Equity Research

                Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

                by Zacks Equity Research

                Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

                  Kevin Cook headshot

                  CRISPR Science and Stocks: Knowing Enough to Invest

                  by Kevin Cook

                  Can you learn enough about the science and the companies to invest with confidence?

                    Zacks Equity Research

                    Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

                    by Zacks Equity Research

                    Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?

                      Zacks Equity Research

                      Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                      by Zacks Equity Research

                      Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                        Zacks Equity Research

                        Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

                        by Zacks Equity Research

                        Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?

                          Zacks Equity Research

                          Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA

                          by Zacks Equity Research

                          FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.

                            David Borun headshot

                            Should You Buy the Dip in CRISPR Therapeutics?

                            by David Borun

                            A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?

                              David Borun headshot

                              Is Genome Editing the Next Biotech Breakthrough?

                              by David Borun

                              CRISPR technology is promising to be the foundation the treatment of 1000s of diseases

                                Zacks Equity Research

                                Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?

                                by Zacks Equity Research

                                Is Editas Medicine, Inc. (EDIT) Outperforming Other Medical Stocks This Year?

                                  Zacks Equity Research

                                  Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                                  by Zacks Equity Research

                                  Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                                    Kevin Cook headshot

                                    Why Sarepta (SRPT) Jumped and We Sold

                                    by Kevin Cook

                                    Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet

                                      Kevin Cook headshot

                                      Healthcare Heroes That Aren't Done Yet

                                      by Kevin Cook

                                      Key growth stocks across medical industries tell you the megatrends are in full force for years to come

                                        Zacks Equity Research

                                        Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher

                                        by Zacks Equity Research

                                        Editas Medicine (EDIT) was a big mover last session, as the company saw its shares rise more than 13% on the day amid huge volumes.

                                          Kevin Cook headshot

                                          Bitcoin or CRISPR: Which is the Bigger Disruptor?

                                          by Kevin Cook

                                          In just 5 years, two new "exponential technologies" have been created that will dramatically change the world

                                            Zacks Equity Research

                                            What's in the Cards for Adverum (ADVM) This Earnings Season?

                                            by Zacks Equity Research

                                            Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                                              Zacks Equity Research

                                              Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3%

                                              by Zacks Equity Research

                                              Editas Medicine, Inc. (EDIT) moved big moved last session, as its shares rose over 11% on the day.

                                                Zacks Equity Research

                                                What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

                                                by Zacks Equity Research

                                                Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

                                                  Zacks Equity Research

                                                  Why Editas Medicine (EDIT) Might Surprise This Earnings Season

                                                  by Zacks Equity Research

                                                  Investors are always looking for stocks that are poised to beat at earnings season and Editas Medicine, Inc. (EDIT) may be one such company.